Opdualag® (nivolumab and relatlimab-rmbw) is a prescription medicine used to treat adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). It is not known if Opdualag is safe and effective when used in children younger than 12 years of age or older who weigh less than 88 pounds (40 kg), or in children younger than 12 years of age.
Opdualag is a combination of 2 immunotherapies available in a single vial of 240 mg nivolumab and 80 mg relatlimab per 20 mL,* with a list price of $15,421.97. Most patients will not pay this amount.†
*Opdualag is a premixed prescription medication of nivolumab and relatlimab in the same vial that is prepared and given as a single intravenous (IV) infusion by your healthcare team. Adult patients and pediatric patients 12 years of age or older who weigh at least 40 kg will receive 2 vials (480 mg nivolumab and 160 mg relatlimab) per treatment every 4 weeks.
†This price does not include the cost of administration or infusion center costs. This list price is current as of 07/01/2025.
BMS Access Support® provides resources to help patients understand their insurance coverage, offers educational materials to support patients throughout their treatment journey, and provides information on financial support options, including co-pay assistance for eligible, commercially insured patients*.
Please visit BMS Access Support, or call BMS Access Support at 1-800-861-0048, 8AM–8PM EST, Monday–Friday.
*Restrictions apply. Please click here for full Terms and Conditions, including complete eligibility requirements.
What is the most important information I should know about Opdualag?
Opdualag is a medicine that may treat a type of skin cancer called melanoma by working with your immune system. Opdualag can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time.
Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:
Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with Opdualag. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:
Getting medical help right away may help keep these problems from becoming more serious. Your healthcare team will check you for these problems during treatment with Opdualag. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop your treatment with Opdualag if you have severe side effects.
Opdualag can cause serious side effects, including:
The most common side effects of Opdualag include: muscle and bone pain; tiredness; decreased red blood cell and white blood cell counts; increased liver function test results; rash; itching, diarrhea; decreased salt (sodium) in your blood.
These are not all the possible side effects of Opdualag. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before receiving Opdualag, tell your healthcare provider if you:
Females who are able to become pregnant:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
INDICATION:
Opdualag® (nivolumab and relatlimab-rmbw) is a prescription medicine used to treat adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). It is not known if Opdualag is safe and effective when used in children younger than 12 years of age or who weigh less than 88 pounds (40 kg), or in children younger than 12 years of age.
Please see U.S. Full Prescribing Information and Medication Guide for Opdualag.
You are now leaving this Bristol Myers Squibb site.
This internet site may provide links or references to other sites. Bristol Myers Squibb has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this internet site.
Would you like to leave this site?